Biotech | April 06, 2022
Aizon partners with TetraScience to help pharma companies speed up drug manufacturing efficiently
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The partnership demonstrates increasing adoption of tetra data to create unrestricted innovation
The new facility is scheduled to start operation in the first half of 2024
Trescal provides precision calibration expertise in every industry, geography and instrument across the world
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
Supply increase to help meet growing global demand
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Subscribe To Our Newsletter & Stay Updated
